When aberrantly expressed, Cripto can drive tumor initiation and progression in multiple tumor types, including prostate cancer [2], breast cancer [3], colon cancer [4], hepatocellular carcinoma [5], glioblastoma [6], and lung cancer [7]. Here, CRIPTO is linked to hepatocellular carcinoma.